CN Patent

CN106866492B — 帕比司他乳酸盐晶型ii及其制备方法和用途

Assigned to Jiangsu Hansoh Pharmaceutical Group Co Ltd · Expires 2021-11-26 · 4y expired

What this patent protects

本发明涉及帕比司他乳酸盐晶型II及其制备方法和用途,具体是N‑羟基‑3‑[4‑[[[2‑(2‑甲基‑1H‑吲哚‐3‐基)乙基]氨基]甲基]苯基]‐(2E)‐2‐丙烯酰胺乳酸盐晶型II及其制备方法，以及含有治疗有效量的该晶型的药物组合物和其在制备治疗多发性骨髓瘤的药物中的应用。本发明的晶型，通过将帕比司他与乳酸反应，加入晶种诱导制得。本发明的晶型，稳定性好、溶解度高。

USPTO Abstract

本发明涉及帕比司他乳酸盐晶型II及其制备方法和用途,具体是N‑羟基‑3‑[4‑[[[2‑(2‑甲基‑1H‑吲哚‐3‐基)乙基]氨基]甲基]苯基]‐(2E)‐2‐丙烯酰胺乳酸盐晶型II及其制备方法，以及含有治疗有效量的该晶型的药物组合物和其在制备治疗多发性骨髓瘤的药物中的应用。本发明的晶型，通过将帕比司他与乳酸反应，加入晶种诱导制得。本发明的晶型，稳定性好、溶解度高。

Drugs covered by this patent

Patent Metadata

Patent number
CN106866492B
Jurisdiction
CN
Classification
—
Expires
2021-11-26
Drug substance claim
No
Drug product claim
No
Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.